|
1
|
Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Yoshino T, Kuwata T, Shitara K. Corrigendum to "Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer": [ESMO Open 8 (2023) 100762]. ESMO Open 2024; 9:102232. [PMID: 38194883 PMCID: PMC10820305 DOI: 10.1016/j.esmoop.2023.102232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2024] Open
Affiliation(s)
- Y Kubota
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba; Department of Clinical Oncology, St. Marianna, University School of Medicine, Kanagawa
| | - A Kawazoe
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - S Mishima
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - Y Nakamura
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - D Kotani
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - Y Kuboki
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - H Bando
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - T Kojima
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - T Doi
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - T Yoshino
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - T Kuwata
- Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan; Department of Genetics and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan
| | - K Shitara
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba.
| |
Collapse
|
|
2
|
Takeda Y, Kato T, Sabrina S, Naito S, Ito H, Emi N, Kuboki Y, Takai Y, Fukuhara H, Ushijima M, Narisawa T, Yagi M, Kanno H, Sakurai T, Nishida H, Araki A, Shimotai Y, Nagashima M, Nouchi Y, Saitoh S, Nara H, Tsuchiya N, Asao H. Intracellular Major Histocompatibility Complex Class II and C-X-C Motif Chemokine Ligand 10-Expressing Neutrophils Indicate the State of Anti-Tumor Activity Induced by Bacillus Calmette-Guérin. Biomedicines 2023; 11:3062. [PMID: 38002062 PMCID: PMC10669614 DOI: 10.3390/biomedicines11113062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Revised: 10/20/2023] [Accepted: 11/07/2023] [Indexed: 11/26/2023] Open
Abstract
(1) Background: Inflammatory responses induce the formation of both anti-tumor and pro-tumor neutrophils known as myeloid-derived suppressor cells (MDSCs). Intermittent intravesical infusion of Bacillus Calmette-Guérin (BCG) is an established cancer immunotherapy for non-muscle-invasive bladder cancer (NMIBC). However, the types of neutrophils induced via the inflammatory response to both tumor-bearing and BCG remain unclear. (2) Methods: We therefore analyzed neutrophil dynamics in the peripheral blood and urine of patients with NMIBC who received BCG therapy. Further, we analyzed the effects of BCG in a mouse intraperitoneal tumor model. (3) Results: BCG therapy induced the formation of CXCL10 and MHC class II-positive neutrophils in the urine of patients with NMIBC but did not induce MDSC formation. CXCL10- and MHC class II-expressing neutrophils were detected in peritoneal exudate cells formed after BCG administration. Partial neutrophil depletion using an anti-Ly6G antibody suppressed the upregulation of CXCL10 and MHC class II in neutrophils and reversed the anti-tumor activity of BCG in mouse models. (4) Conclusions: These results indicated that intracellular MHC class II- and CXCL10-expressing neutrophils indicate the state of anti-tumor activity induced via BCG. The status of neutrophils in mixed inflammation of immunosuppressive and anti-tumor responses may therefore be useful for evaluating immunological systemic conditions.
Collapse
Affiliation(s)
- Yuji Takeda
- Department of Immunology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (S.S.); (N.E.); (M.N.); (Y.N.); (S.S.); (H.A.)
| | - Tomoyuki Kato
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (T.K.); (S.N.); (H.I.); (Y.K.); (Y.T.); (H.F.); (M.U.); (T.N.); (M.Y.); (H.K.); (T.S.); (H.N.); (N.T.)
| | - Saima Sabrina
- Department of Immunology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (S.S.); (N.E.); (M.N.); (Y.N.); (S.S.); (H.A.)
| | - Sei Naito
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (T.K.); (S.N.); (H.I.); (Y.K.); (Y.T.); (H.F.); (M.U.); (T.N.); (M.Y.); (H.K.); (T.S.); (H.N.); (N.T.)
| | - Hiromi Ito
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (T.K.); (S.N.); (H.I.); (Y.K.); (Y.T.); (H.F.); (M.U.); (T.N.); (M.Y.); (H.K.); (T.S.); (H.N.); (N.T.)
| | - Naoto Emi
- Department of Immunology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (S.S.); (N.E.); (M.N.); (Y.N.); (S.S.); (H.A.)
| | - Yuya Kuboki
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (T.K.); (S.N.); (H.I.); (Y.K.); (Y.T.); (H.F.); (M.U.); (T.N.); (M.Y.); (H.K.); (T.S.); (H.N.); (N.T.)
| | - Yuki Takai
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (T.K.); (S.N.); (H.I.); (Y.K.); (Y.T.); (H.F.); (M.U.); (T.N.); (M.Y.); (H.K.); (T.S.); (H.N.); (N.T.)
| | - Hiroki Fukuhara
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (T.K.); (S.N.); (H.I.); (Y.K.); (Y.T.); (H.F.); (M.U.); (T.N.); (M.Y.); (H.K.); (T.S.); (H.N.); (N.T.)
| | - Masaki Ushijima
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (T.K.); (S.N.); (H.I.); (Y.K.); (Y.T.); (H.F.); (M.U.); (T.N.); (M.Y.); (H.K.); (T.S.); (H.N.); (N.T.)
| | - Takafumi Narisawa
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (T.K.); (S.N.); (H.I.); (Y.K.); (Y.T.); (H.F.); (M.U.); (T.N.); (M.Y.); (H.K.); (T.S.); (H.N.); (N.T.)
| | - Mayu Yagi
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (T.K.); (S.N.); (H.I.); (Y.K.); (Y.T.); (H.F.); (M.U.); (T.N.); (M.Y.); (H.K.); (T.S.); (H.N.); (N.T.)
| | - Hidenori Kanno
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (T.K.); (S.N.); (H.I.); (Y.K.); (Y.T.); (H.F.); (M.U.); (T.N.); (M.Y.); (H.K.); (T.S.); (H.N.); (N.T.)
| | - Toshihiko Sakurai
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (T.K.); (S.N.); (H.I.); (Y.K.); (Y.T.); (H.F.); (M.U.); (T.N.); (M.Y.); (H.K.); (T.S.); (H.N.); (N.T.)
| | - Hayato Nishida
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (T.K.); (S.N.); (H.I.); (Y.K.); (Y.T.); (H.F.); (M.U.); (T.N.); (M.Y.); (H.K.); (T.S.); (H.N.); (N.T.)
| | - Akemi Araki
- Department of Immunology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (S.S.); (N.E.); (M.N.); (Y.N.); (S.S.); (H.A.)
| | - Yoshitaka Shimotai
- Department of Infectious Diseases, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan;
| | - Mikako Nagashima
- Department of Immunology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (S.S.); (N.E.); (M.N.); (Y.N.); (S.S.); (H.A.)
| | - Yusuke Nouchi
- Department of Immunology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (S.S.); (N.E.); (M.N.); (Y.N.); (S.S.); (H.A.)
| | - Shinichi Saitoh
- Department of Immunology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (S.S.); (N.E.); (M.N.); (Y.N.); (S.S.); (H.A.)
| | - Hidetoshi Nara
- Department of Biological Sciences, Faculty of Science and Engineering, Ishinomaki Senshu University, Miyagi 986-8580, Japan;
| | - Norihiko Tsuchiya
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (T.K.); (S.N.); (H.I.); (Y.K.); (Y.T.); (H.F.); (M.U.); (T.N.); (M.Y.); (H.K.); (T.S.); (H.N.); (N.T.)
| | - Hironobu Asao
- Department of Immunology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan; (S.S.); (N.E.); (M.N.); (Y.N.); (S.S.); (H.A.)
| |
Collapse
|
|
3
|
Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Yoshino T, Kuwata T, Shitara K. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open 2023; 8:100762. [PMID: 36610262 PMCID: PMC10024138 DOI: 10.1016/j.esmoop.2022.100762] [Citation(s) in RCA: 27] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2022] [Revised: 12/03/2022] [Accepted: 12/06/2022] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND We conducted comprehensive clinical and molecular characterization of claudin 18.2 expression (CLDN18.2) in advanced gastric or gastroesophageal junction cancer (GC/GEJC). PATIENTS AND METHODS Patients with advanced GC/GEJC who received systemic chemotherapy from October 2015 to December 2019 with available tumor specimens were analyzed. We evaluated clinicopathological features of CLDN18.2 expression with four molecular subtypes: mismatch repair deficient, Epstein-Barr virus-positive, human epidermal growth factor receptor 2-positive, and others. In addition, programmed death-ligand 1 (PD-L1) combined positive score (CPS), genomic alterations, and the expression of immune cell markers were assessed. Clinical outcomes of standard first- or second-line chemotherapy and subsequent anti-programmed cell death protein 1 (anti-PD-1) therapy were also investigated according to CLDN18.2 expression. RESULTS Among 408 patients, CLDN18.2-positive (moderate-to-strong expression in ≥75%) was identified in 98 patients (24.0%) with almost equal distribution in the four molecular subtypes or CPS subgroups. CLDN18.2-positive was associated with Borrmann type 4, KRAS amplification, low CD16, and high CD68 expression. Overall survival with first-line chemotherapy was not significantly different between CLDN18.2-positive and -negative groups [median 18.4 versus 20.1 months; hazard ratio 1.26 (95% confidence interval 0.89-1.78); P = 0.191] regardless of stratification by PD-L1 CPS ≥5. Progression-free survival and objective response rates of first- and second-line chemotherapy, and anti-PD-1 therapy also showed no significant differences according to CLDN18.2 status. CONCLUSIONS CLDN18.2 expression in advanced GC/GEJC was associated with some clinical and molecular features but had no impact on treatment outcomes with chemotherapy or checkpoint inhibition. CLDN18.2-positive also had no impact on overall survival. This information could be useful to interpret the results from currently ongoing clinical trials of CLDN18.2-targeted therapies for advanced GC/GEJC and to consider a treatment strategy for CLDN18.2-positive GC/GEJC.
Collapse
Affiliation(s)
- Y Kubota
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba; Department of Clinical Oncology, St. Marianna University School of Medicine, Kanagawa
| | - A Kawazoe
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - S Mishima
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - Y Nakamura
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - D Kotani
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - Y Kuboki
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - H Bando
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - T Kojima
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - T Doi
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - T Yoshino
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - T Kuwata
- Departments of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan; Genetics and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan
| | - K Shitara
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba.
| |
Collapse
|
|
4
|
Kuboki Y, Yaeger R, Fakih M, Strickler J, Masuishi T, Kim EH, Bestvina C, Langer C, Krauss J, Puri S, Cardona P, Chang E, Tran Q, Hong D. 45MO Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
|
5
|
Masuishi T, Kuboki Y, Fakih M, Strickler J, Furqan M, Kim E, Cardona P, Tran Q, Chan E, Hong D. 444TiP Trial in progress: A phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment naïve and previously treated metastatic colorectal cancer (CodeBreaK 101). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
|
6
|
Harding J, Hofheinz R, Elez Fernandez M, Kuboki Y, Rasco D, Cecchini M, Shen L, Archuadze S, Geng J, Haderk F, Pant S. 371P A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
|
7
|
Kuboki Y, Yaeger R, Fakih M, Strickler J, Masuishi T, Kim E, Bestvina C, Langer C, Krauss J, Puri S, Cardona P, Chan E, Tran Q, Hong D. 315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
|
8
|
Taniguchi H, Kuboki Y, Watanabe J, Terazawa T, Kawakami H, Yokota M, Nakamura M, Kotaka M, Sugimoto N, Ojima H, Oki E, Kajiwara T, Moriwaki T, Takayama T, Denda T, Tamura T, Sunakawa Y, Ishihara S, Nakajima T, Morita S, Shirao K, Yoshino T. SO-19 Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
|
9
|
Kopetz S, Van Cutsem E, Kuboki Y, Johnson B, Katakabe T, Geng J, Archuadze S, Shen L. P-123 A phase Ia/Ib, open-label, dose-escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy in patients with advanced gastrointestinal cancers. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
|
10
|
Price T, Prenen H, Lugowska I, Falchook G, Monzon J, Arkenau H, Chawla S, Hui M, Kuboki Y, Dziadziuszko R, Ozawa Y, Elez Fernandez M, Rocha Lima C, Subbiah V, Tan D, Wang K, Hindoyan A, Shi W, Kistler M, Hashemi Sadraei N. 142P Updated results from a phase I, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
|
11
|
Kuboki Y, Shitara K, Morizane C, Kojima T, Yoh K, Sakai D, Tahara M, Hirai H, Kurokawa Y, Kato T, Doi T. 1383P Phase I study of the irreversible FGFR inhibitor futibatinib in Japanese patients with advanced solid tumors: Updated dose expansion results and activity in gastric cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
|
12
|
Oki E, Watanabe J, Sato T, Kagawa Y, Kuboki Y, Ikeda M, Ueno H, Kato T, Kusumoto T, Masuishi T, Yamaguchi K, Kanazawa A, Nishina T, Uetake H, Yamanaka T, Yoshino T. Impact of the 12-gene recurrence score assay on deciding adjuvant chemotherapy for stage II and IIIA/B colon cancer: the SUNRISE-DI study. ESMO Open 2021; 6:100146. [PMID: 33984677 PMCID: PMC8134704 DOI: 10.1016/j.esmoop.2021.100146] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2021] [Revised: 03/26/2021] [Accepted: 04/12/2021] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND Recent advances in adjuvant chemotherapy for early colon cancer have widened physicians' recommendations on the regimen and duration (3 or 6 months) of the treatment. We conducted this prospective study to evaluate whether the 12-gene recurrence score (12-RS) assay affected physicians' recommendations on adjuvant treatment selection. PATIENTS AND METHODS Patients with stage IIIA/IIIB or stage II colon cancer were enrolled. After the patients discussed adjuvant treatment with their treating physicians, the physicians filled in the questionnaire before assay indicating the treatment recommendation. When the 12-RS assay results were available, the physicians again filled in the questionnaire after assay. The primary endpoint was the rate of change in treatment recommendations from before to after the assay, with a threshold rate of change being 20%. Patients with stage IIIA/B to II were enrolled in a ratio of 2 : 1. RESULTS Overall, the treatment recommendations changed in 40% of cases after obtaining 12-RS assay results. Recommendations were changed in 45% (80/178; 95% confidence interval, 37% to 53%; P < 0.001) and 30% (29/97; 95% confidence interval, 21% to 40%; P < 0.001) of patients with stage IIIA/B and II colon cancer, respectively. Patients with stage IIIA/B cancer had significantly more change than those with stage II cancer (P = 0.0148). From before to after the 12-RS assay, the percentage of patients whose physicians reported being confident in their treatment recommendations significantly increased from 54% to 81% in stage IIIA/B (P < 0.001) and from 65% to 83% in stage II (P < 0.001). CONCLUSION Our study confirmed the usefulness of the 12-RS assay in aiding the physician-patient decision-making process for tailoring adjuvant chemotherapy for stage IIIA/B colon cancer.
Collapse
Affiliation(s)
- E Oki
- Department of Surgery and Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
| | - J Watanabe
- Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan
| | - T Sato
- Department of Colorectal Surgery, Kitasato University Hospital, Kanagawa, Japan
| | - Y Kagawa
- Department of Surgery, Kansai Rosa Hospital, Hyogo, Japan
| | - Y Kuboki
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
| | - M Ikeda
- Department of Surgery, Hyogo College of Medicine, Hyogo, Japan
| | - H Ueno
- Department of Surgery, National Defense Medical College, Saitama, Japan
| | - T Kato
- Department of Surgery, NHO Osaka National Hospital, Osaka, Japan
| | - T Kusumoto
- Department of Gastroenterological Surgery, NHO National Kyushu Medical Center, Fukuoka, Japan
| | - T Masuishi
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan
| | - K Yamaguchi
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - A Kanazawa
- Department of Gastroenterological Surgery, Shimane Prefectural Central Hospital, Shimane, Japan
| | - T Nishina
- Department of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center, Ehime, Japan
| | - H Uetake
- Department of Specialized Surgeries, Tokyo Medical and Dental University, Tokyo, Japan
| | - T Yamanaka
- Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.
| | - T Yoshino
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
| |
Collapse
|
|
13
|
Strickler J, Fakih M, Price T, Desai J, Durm G, Krauss J, Kuboki Y, Kim T, Sacher A, Henary H, Kim J, Hong D. 83MO AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
|
14
|
Morizane C, Kojima T, Kuboki Y, Bando H, Matsubara N, Shitara K, Yoh K, Hirai H, Kato T, Doi T. 544P Phase I study of the irreversible FGFR inhibitor (i) futibatinib (FBN; TAS-120) in Japanese patients (pts) with advanced (adv) solid tumours. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
|
15
|
Strickler J, Fakih M, Price T, Desai J, Durm G, Krauss J, Kuboki Y, Kim T, Sacher A, Henary H, Kim J, Hong D. SO-24 AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: Results from the CodeBreak 100 phase 1 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
|
16
|
Harding J, Hofheinz R, Elez E, Kuboki Y, Geng J, Schmohl M, Dowling E, Feng Y, Rasco D. P-169 A first-in-human phase Ia/b, open-label, multicentre, dose-escalation study of BI 905711 in patients with advanced gastrointestinal cancers. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
|
17
|
Naito S, Kato T, Ichiyanagi O, Narisawa T, Kurokawa M, Yagi M, Ushijima M, Ozawa M, Kanno H, Kurota Y, Fukuhara H, Kuboki Y, Yamagishi A, Sakurai T, Nishida H, Yamanobe T, Tsuchiya N. New prognostic model for synchronous metastatic renal cell carcinoma. Int J Urol 2020; 27:448-456. [DOI: 10.1111/iju.14215] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2019] [Accepted: 02/03/2020] [Indexed: 01/27/2023]
Affiliation(s)
- Sei Naito
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Tomoyuki Kato
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Osamu Ichiyanagi
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Takafumi Narisawa
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Masayuki Kurokawa
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Mayu Yagi
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Masaki Ushijima
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Michinobu Ozawa
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Hidenori Kanno
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Yuta Kurota
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Hiroki Fukuhara
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Yuya Kuboki
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Atsushi Yamagishi
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Toshihiko Sakurai
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Hayato Nishida
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Takuya Yamanobe
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| | - Norihiko Tsuchiya
- Department of Urology Yamagata University Faculty of Medicine Yamagata Japan
| |
Collapse
|
|
18
|
Watanabe J, Sato T, Kagawa Y, Oki E, Kuboki Y, Ikeda M, Ueno H, Kato T, Kusumoto T, Masuishi T, Yamaguchi K, Kanazawa A, Nishina T, Uetake H, Yamanaka T, Yoshino T. SUNRISE-DI study: decision impact of the 12-gene recurrence score (12-RS) assay on adjuvant chemotherapy recommendation for stage II and IIIA/B colon cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz154.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
19
|
Kotani D, Kuboki Y, Yasuda K, Nakamura Y, Kawazoe A, Bando H, Taniguchi H, Shitara K, Yoshino T. Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
20
|
Hara H, Yoshino T, Taniguchi H, Akagi K, Shitara K, Masuishi T, Kuboki Y, Shimamoto T, Ueki K, Han S, Noguchi K, Diaz L. Phase II KEYNOTE-164 study of pembrolizumab (pembro) monotherapy for patients (pts) with previously treated, mismatch repair–Deficient (dMMR) advanced colorectal cancer (CRC): Primary and Japan subgroup analyses. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
21
|
Yamazaki K, Yasui H, Yamaguchi K, Kagawa Y, Kuboki Y, Yoshino T, Gamoh M, Komatsu Y, Satake H, Goto M, Tanioka H, Oki E, Kotaka M, Makiyama A, Denda T, Soeda J, Shibya K, Iwata M, Oba K, Kato T. A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
22
|
Fukuhara H, Kakizaki H, Kaneko H, Yamanobe T, Ushijima M, Kuboki Y, Tsuchiya N. Successful Treatment with Paclitaxel, Carboplatin, and Gemcitabine as Second-line Chemotherapy for Recurrent Urothelial Carcinoma of the Bladder with Glandular Differentiation After Radical Cystectomy: A Case Report. Urol Case Rep 2017; 15:11-13. [PMID: 28932689 PMCID: PMC5595231 DOI: 10.1016/j.eucr.2017.08.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2017] [Revised: 07/30/2017] [Accepted: 08/01/2017] [Indexed: 11/01/2022] Open
Abstract
Urothelial carcinoma of the bladder (UCB) with glandular differentiation is a histological variant (HV) that is more likely to have positive extravesical tumors or nodes than those in pure UCB. Cisplatin-based neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) is more effective for pure UCB; however, few reports are available on second-line chemotherapy for recurrence of UCB with HV. Here we report a 65-year-old Japanese male diagnosed with local recurrence UCB with HV after NAC + RC who safely achieved complete response with paclitaxel, carboplatin, and gemcitabine combination chemotherapy.
Collapse
Affiliation(s)
- Hiroki Fukuhara
- Department of Urology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata City, Yamagata Prefecture, 998-9585, Japan
| | - Hiroshi Kakizaki
- Department of Urology, Nihonkai General Hospital, 30 Akiho-cho, Sakata City, Yamagata Prefecture, 998-8501, Japan
| | - Hisashi Kaneko
- Department of Urology, Nihonkai General Hospital, 30 Akiho-cho, Sakata City, Yamagata Prefecture, 998-8501, Japan
| | - Takuya Yamanobe
- Department of Urology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata City, Yamagata Prefecture, 998-9585, Japan
| | - Masaki Ushijima
- Department of Urology, Nihonkai General Hospital, 30 Akiho-cho, Sakata City, Yamagata Prefecture, 998-8501, Japan
| | - Yuya Kuboki
- Department of Urology, Nihonkai General Hospital, 30 Akiho-cho, Sakata City, Yamagata Prefecture, 998-8501, Japan
| | - Norihiko Tsuchiya
- Department of Urology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata City, Yamagata Prefecture, 998-9585, Japan
| |
Collapse
|
|
23
|
Kuboki Y, Matsubara N, Bando H, Shitara K, Yoh K, Kojima T, Ohno I, Takahashi H, Harano K, Kondo S, Hirai H, Morizane C, Doi T. First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
24
|
Yamazaki K, Kuboki Y, Shinozaki E, Hara H, Komatsu Y, Nishina T, Yamaguchi K, Yuki S, Bando H, Asayama M, Tsushima T, Hamauchi S, Nakatsumi H, Kajiwara T, Wakabayashi M, Nomura S, Sato A, Doi T, Ohtsu A, Yoshino T. A Multicentre Phase I/II Study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-task force: EPOC1410). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.042] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
25
|
Ozawa M, Kuboki Y, Suenaga S, Ishii T, Suzuki H, Tsuchiya N. [A CASE OF BLEEDING AFTER PROSTATE BIOPSY WITH CONSERVATIVELY-TREATED GIANT RETROPERITONEAL HEMATOMA WHICH HAD EXTENDED INTRAPERITONEALLY]. Nihon Hinyokika Gakkai Zasshi 2017; 108:114-117. [PMID: 29669975 DOI: 10.5980/jpnjurol.108.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
The patient was a 61-year old male on maintenance dialysis who underwent transrectal prostate biopsy due to a high PSA level. The patient started suffering from intense pain in the anal region 1 hour after the biopsy, and in 7 hours, intense lower abdominal pain and bilious vomiting developed. Progressive anemia was observed with a giant retroperitoneal hematoma which had partially extended intraperitoneally on a non-contrast CT image. These findings might have been caused by arterial bleeding which occurred during the prostate biopsy. The general condition was stable, and the symptoms were improved by blood transfusion and conservative treatments.
Collapse
Affiliation(s)
| | - Yuya Kuboki
- Department of Urology, Yamagata City Hospital SAISEIKAN
| | | | - Tatsuya Ishii
- Department of Urology, Yamagata City Hospital SAISEIKAN
| | | | | |
Collapse
|
|
26
|
Doi A, Bando H, Kawazoe A, Fukuoka S, Kuboki Y, Shitara K, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T. 180P Clinical outcome of anal squamous cell carcinoma treated with chemoradiotherapy with 5-fluorouracil plus mitomycin C. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00338-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
|
27
|
Doi A, Bando H, Kawazoe A, Fukuoka S, Kuboki Y, Shitara K, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T. 180P Clinical outcome of anal squamous cell carcinoma treated with chemoradiotherapy with 5-fluorouracil plus mitomycin C. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw581.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
|
28
|
Tamura K, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Fujisaki Y, Yver A, Doi T. Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.07] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
29
|
Nishina T, Kuboki Y, Shinozaki E, Fukuoka S, Kajiwara T, Shitara K, Yamaguchi K, Komatsu Y, Yuki S, Yamazaki K, Hara H, Mochizuki N, Fukutani M, Hasegawa H, Matsuda S, Wakabayashi M, Nomura S, Sato A, Ohtsu A, Yoshino T. A multicentre phase I/II study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-TASK FORCE: EPOC1410); Phase I results. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
30
|
Doi T, Shitara K, Naito Y, Kuboki Y, Kojima T, Hosono A, Yoshino T, Kawamoto H, Tadayasu Y, Ugai H, Takeuchi Y, Bogenrieder T, Yoh K. Phase I dose escalation (esc) trial of weekly intravenous (i.v.) BI 836845 in Japanese patients (pts) with advanced solid tumors. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
31
|
Yoshino T, Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T, Mochizuki N, Fukutani M, Nakamoto M, Hasegawa H, Sugama A, Nomura S, Sato A, Ohtsu A. PD-013 Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw200.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
|
32
|
Kuboki Y, Yamashita S, Niwa T, Ushijima T, Nagatsuma A, Kuwata T, Yoshino T, Doi T, Ochiai A, Ohtsu A. Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. Ann Oncol 2015; 27:127-33. [PMID: 26489445 DOI: 10.1093/annonc/mdv508] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Accepted: 10/09/2015] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND In advanced gastric cancer (AGC), most clinical trials are designed on the basis of protein expression or gene amplification of specific genes. Recently, next-generation sequencing (NGS) allowed us to comprehensively profile the tumor gene status. This study aimed to elucidate the profiling between gene alterations and protein expression in AGC to aid in future clinical trials on AGC. PATIENTS AND METHODS Formalin-fixed, paraffin-embedded tumor samples from 121 stage III/IV gastric cancer patients were examined for protein expression of tyrosine kinase receptors (RTKs; ERBB2, EGFR, c-MET, and FGFR2) using immunohistochemistry (IHC). Furthermore, 409 cancer-related genes were sequenced to detect mutations and copy number variations using NGS. RESULTS Most ERBB2 overexpression (IHC 3+) cases (80.0%) had ERBB2 amplification and did not have other RTK amplification or oncogene mutations. However, one-fourth of MET overexpression cases (25.0%) had ERBB2 alterations. EGFR and FGFR2 overexpression cases had ERBB2 alterations or other gene alterations such as KRAS or PIK3CA. On the other hand, most of the four RTK amplification cases (88.2%) were mutually exclusive with each amplification. However, RTK amplification did not simply correlate with protein overexpression, whereas cases with RTK high-level amplification had protein overexpression and rarely showed other co-existing gene alterations. CONCLUSION AGC involves a complicated arrangement of protein expression and gene alterations. Comprehensive analyses of NGS and IHC will be necessary to design the optimal therapy for treating the appropriate population of patients in future clinical trials.
Collapse
Affiliation(s)
- Y Kuboki
- Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba Medical Science Program, Graduate School of Medicine, Keio University, Tokyo Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - S Yamashita
- Division of Epigenomics, National Cancer Center Research Institute, Tokyo
| | - T Niwa
- Division of Epigenomics, National Cancer Center Research Institute, Tokyo
| | - T Ushijima
- Division of Epigenomics, National Cancer Center Research Institute, Tokyo
| | - A Nagatsuma
- Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba
| | - T Kuwata
- Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba
| | - T Yoshino
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - T Doi
- Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba
| | - A Ochiai
- Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba Medical Science Program, Graduate School of Medicine, Keio University, Tokyo
| | - A Ohtsu
- Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, Japan
| |
Collapse
|
|
33
|
Yamazaki K, Kuboki Y, Nishina T, Shinozaki E, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T, Mochizuki N, Fukutani M, Nakamoto M, Hasegawa Y, Sugama A, Nomura S, Sato A, Ohtsu A, Yoshino T. 2116 A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31038-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
|
34
|
Okamoto W, Shitara K, Takahashi H, Naito Y, Kuwata T, Bando H, Kuboki Y, Matsumoto S, Miki I, Yamanaka T, Ohtsu A, Esumi H, Ochiai A, Yoshino T, Tsuchihara K. 465 Detection of somatic mutations and gene amplification using Oncomine Cancer Research Panel with biopsy samples from patients with advanced gastric cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30299-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
|
35
|
Nishina T, Kuboki Y, Shinozaki E, Yamazaki K, Kajiwara T, Shitara K, Matsumoto T, Tsushima T, Okamoto W, Mochizuki N, Nomura S, Sato A, Ohtsu A, Yoshino T. PD-017 A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv234.16] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
|
36
|
Shinozaki E, Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Machida N, Yuki S, Ooki A, Kajiura S, Kimura T, Yamanaka T, Sasaki T, Shitara K, Nagatsuma A, Yoshino T, Ochiai A, Ohtsu A. Prognostic Impact of Her2, Egfr, and C-Met Status on Overall Survival of Advanced Gastric Cancer Patients Treated with Standard Chemotherapy Without Trastuzumab in a First-Line Treatment: a Japanese Multicenter Collaborative Retrospective Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
|
37
|
Matsuura T, Akizuki T, Hoshi S, Ikawa T, Kinoshita A, Sunaga M, Oda S, Kuboki Y, Izumi Y. Effect of a tunnel-structured β-tricalcium phosphate graft material on periodontal regeneration: a pilot study in a canine one-wall intrabony defect model. J Periodontal Res 2014; 50:347-55. [DOI: 10.1111/jre.12213] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/30/2014] [Indexed: 12/28/2022]
Affiliation(s)
- T. Matsuura
- Department of Periodontology; Graduate School of Medical and Dental Science; Tokyo Medical and Dental University; Tokyo Japan
| | - T. Akizuki
- Department of Periodontology; Graduate School of Medical and Dental Science; Tokyo Medical and Dental University; Tokyo Japan
- Division of Periodontology; Department of Oral Science; Graduate School of Dentistry; Kanagawa Dental University; Kanagawa Japan
| | - S. Hoshi
- Department of Periodontology; Graduate School of Medical and Dental Science; Tokyo Medical and Dental University; Tokyo Japan
| | - T. Ikawa
- Department of Periodontology; Graduate School of Medical and Dental Science; Tokyo Medical and Dental University; Tokyo Japan
| | - A. Kinoshita
- Department of Educational Media Development; Institute for Library and Media Information Technology; Tokyo Medical and Dental University; Tokyo Japan
| | - M. Sunaga
- Department of Educational Media Development; Institute for Library and Media Information Technology; Tokyo Medical and Dental University; Tokyo Japan
| | - S. Oda
- Oral Diagnosis and General Dentistry; University Hospital of Dentistry; Tokyo Medical and Dental University; Tokyo Japan
| | - Y. Kuboki
- Graduate School of Dental Medicine; Hokkaido University; Sapporo Japan
| | - Y. Izumi
- Department of Periodontology; Graduate School of Medical and Dental Science; Tokyo Medical and Dental University; Tokyo Japan
- Global Center of Excellence Program; International Research Center for Molecular Science in Tooth and Bone Diseases (GCOE Program); Tokyo Japan
| |
Collapse
|
|
38
|
Kuboki Y, Yoshino T, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Ohtsu A. 6005 ORAL A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71650-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
|
39
|
Horikawa Y, Tsuchiya N, Yuasa K, Narita S, Saito M, Takayama K, Nara T, Tsuruta H, Obara T, Numakura K, Satoh S, Habuchi T, Hu X, Guo J, Lin Z, Sun L, Xu Z, Cang C, Wang G, Kanda T, Sakamoto K, Matsuki A, Ohashi R, Hirota S, Fujimori Y, Matsuda Y, Yajima K, Kosugi S, Hatakeyama K, Kitahara K, Watanabe M, Nakazono S, Wada N, Kakizaki H, Li J, Gong FJ, Sun PN, Shen L, Li Q, Li N, Qiu M, Liu J, Yi C, Luo D, Li Z, Gou H, Yang Y, Cao D, Shen Y, Wang X, Xu F, Bi F, Li Q, Zhang X, Li N, Wei W, Luo HY, Wang ZQ, Wang FH, Qiu MZ, Teng KY, Ruan DY, He YJ, Li YH, Xu RH, Matsusaka S, Mizunuma N, Suenaga M, Shinozaki E, Mishima Y, Terui Y, Hatake K, Nara E, Kodaira M, Mishima Y, Yokoyama M, Saotome T, Terui Y, Takahashi S, Hatake K, Nishimura N, Nakano K, Kodaira M, Ueda K, Yamada S, Mishima Y, Yokoyama M, Saotome T, Takahashi S, Terui Y, Hatake K, Nozawa M, Mochida Y, Nishigaki K, Nagae S, Uemura H, Oh SY, Jeong CY, Hong SC, Lee WS, Kim HG, Lee GW, Hwang IG, Jang JS, Kwon HC, Kang JH, Ozaka M, Ogura M, Matsusaka S, Shinozaki E, Suenaga M, Chin K, Mizunuma N, Hatake K, Pua PF, Ganzon D, Chan V, Sailaja K, Vishnupriya S, Raghunadharao D, Markandeya G, Reddy PRK, Reddanna P, Praveen D, Sakamoto K, Kanda T, Matsuki A, Takano T, Hanyu T, Yajima K, Kosugi S, Hirota S, Hatakeyama K, Shigekawa T, Ijichi N, Takayama S, Tsuda H, Ikeda K, Horie K, Osaki A, Saeki T, Inoue S, Subhashini J, Rajesh B, Rajesh I, Ravindran P, Takagi K, Chin K, Oba M, Kuboki Y, Ichimura T, Oto M, Kawazoe Y, Watanabe T, Ozaka M, Ogura M, Suenaga M, Shinozaki E, Matsusaka S, Mizunuma N, Hatake K, Ueda K, Saotome T, Yamada S, Nishimura N, Nara E, Nakano K, Kodaira M, Katsube A, Mishima Y, Terui Y, Yokoyama M, Takahashi S, Hatake K, Yao X, Yang Q, Li C, Diao L, Chen X, Yu Z, Zuo W, Wang Y, He Y, Zhang X, Cai S, Wang Z, Xu J, Zhan W, Zhang YF, Misumi M, Takeuchi H, Nakamiya N, Shigekawa T, Matsuura K, Fujiuchi N, Osaki A, Saeki T. CLINICAL OUTCOMES. Jpn J Clin Oncol 2011. [DOI: 10.1093/jjco/hyq254] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
|
40
|
Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ogura M, Kuboki Y, Watanabe T, Ozaka M, Chin K, Hatake K. Effect of the addition of bevacizumab to first-line FOLFOX on efficacy, including response rate, progression-free survival, and overall survival, in patients with metastatic colorectal cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
588 Background: Bevacizumab (BV) is a recombinant, humanized monoclonal antibody against vascular endothelial growth factor. Used in combination with chemotherapy, BV has been shown to improve survival in both first- and second-line treatment for metastatic colorectal cancer (mCRC). However, it was reported that addition of BV to FOLFOX conferred only little survival benefit (Saltz et al. JCO2008). The aim of this study was to assess the efficacy of addition of BV to FOLFOX in first-line treatment for patients with mCRC. Methods: Bevacizumab was approved for mCRC in July 2007 in Japan. This study was conducted at a single institution and comprised 217 consecutive patients receiving first-line treatment for mCRC between 2005 and 2009. The primary objective was to compare survival benefit in patients treated with FOLFOX4 (FF) between 2005 and 2007 with that in patients receiving FOLFOX4+BV 5 mg/kg (FF+BV) between 2007 and 2009. Results: Total number of patients in the FF and FF+BV groups was 132 and 85, respectively. Characteristics of patients were as follows (FF vs. FF+B): median age, 62 yrs (range 28-76 yrs) vs. 60 yrs (range16-74 yrs); ECOG PS0, 98.8% vs. 81.8%; and median follow-up time, 20.8 months vs. 24.4 months. Median progression-free survival (PFS) in the FF and FF+BV groups was 10 months (95% CI, 8.7-11.3) and 17 months (95% CI, 10.2-14.1), while median overall survival (OS) was 21 months (95% CI, 17.9-24.1) and not reached, respectively. Response rate was 46% (95% CI, 37- 54) in FF, and 62% (95% CI, 51-73) in FF+BV. Addition of BV to FOLFOX4 significantly improved PFS (p=0.002) and OS (p<0.001). Conclusions: The additive effect of BV for first-line FOLFOX was reconfirmed. These data indicate potential survival benefits from the addition of BV to FOLFOX in first-line treatment of mCRC. In addition, PFS may be a sensitive indicator of outcome prior to post-treatment. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Suenaga
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - N. Mizunuma
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - S. Matsusaka
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - E. Shinozaki
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - M. Ogura
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - Y. Kuboki
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - T. Watanabe
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - M. Ozaka
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - K. Chin
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - K. Hatake
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| |
Collapse
|
|
41
|
Matsusaka S, Mizunuma N, Suenaga M, Chin K, Shinozaki E, Watanabe T, Kawazoe Y, Kuboki Y, Terui Y, Hatake K. Use of circulating endothelial cells to predict response to FOLFOX4 plus bevacizumab in metastatic colorectal cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
427 Background: The purpose of this study was to identify CEC threshold proposal for determining response to FOLFOX4 plus bevacizumab in metastatic colorectal cancer (mCRC). Methods: All patients were enrolled using institutional review board-approved protocols at the Cancer Institute Hospital and provided informed consent. From July 2007 to June 2008, 33 patients treated with FOLFOX4 plus bevacizumab were enrolled in a prospective study. From January 2007 to June 2007, before bevacizumab was approved by the government in Japan, 31 patients treated with FOLFOX4 as a control were enrolled. The study population consisted of patients aged 18 years or older with histologically proven mCRC. Other inclusion criteria were Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, adequate organ function. CECs of whole blood at the baseline, day 4, 2 weeks after initiation of chemotherapy were isolated and counted using immunomagnetics. Results: There was no correlation between CEC levels and the outcome in the FOLFOX4. In the FOLFOX4 plus bevacizumab, CEC levels at the baseline were significantly associated with the outcome. Patients with 65 or more CECs at the baseline had shorter median PFS (9.2 months), than the median PFS of fewer than 65 CECs at the baseline (18.9 months) in the FOLFOX4 plus bevacizumab (p = 0.003). Patients with 65 or more CECs at the baseline had shorter median OS (23.3 months), than the median OS of fewer than 65 CEC s at the baseline in the FOLFOX4 plus bevacizumab (p = 0.027). In the univariate analysis, lung metastasis, lymph node metastasis, and CEC levels at the baseline predicted PFS. In the univariate Cox regression analyses, peritoneal metastasis, CEC levels at the baseline were associated with OS. In order to evaluate the independent predictive effect of FOLFOX4 plus bevacizumab, multivariate Cox regression analysis was carried out. CEC levels at the baseline were the strongest predictor. Conclusions: A threshold of lower than 65 CEC/4mL at the baseline was a significant predictor of the outcome for colorectal cancer patients treated with FOLFOX4 plus bevacizumab. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Matsusaka
- Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan
| | - N. Mizunuma
- Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan
| | - M. Suenaga
- Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan
| | - K. Chin
- Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan
| | - E. Shinozaki
- Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan
| | - T. Watanabe
- Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan
| | - Y. Kawazoe
- Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan
| | - Y. Kuboki
- Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan
| | - Y. Terui
- Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan
| | - K. Hatake
- Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan
| |
Collapse
|
|
42
|
Suenaga M, Matsusaka S, Watanabe T, Takagi K, Kuboki Y, Ozaka M, Shinozaki E, Chin K, Mizunuma N, Hatake K. Coagulo-fibrinolytic activity as a predictor of efficacy in bevacizumab-combined chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
533 Background: The combination of bevacizumab (BV) and chemotherapy in the first-line and second-line treatment of metastatic colorectal cancer (mCRC) has been shown to improve survival. Bevacizumab is a recombinant, humanized monoclonal antibody against vascular endothelial growth factor. However, the relationship between coagulo-fibrinolytic activity factors and treatment efficacy remains to be clarified. The aim of this study was to determine potential coagulo-fibrinolytic activity markers impacting survival. Methods: Among 119 consecutive patients included in the study, 85 received first-line FOLFOX4 plus BV 5 mg/kg and 34 received second-line FOLFIRI plus BV 5 mg/kg until progression of disease or unmanageable toxicity occurred. Coagulo-fibrinolytic activity factors, including D-dimer, thrombin antithrombin complex (TAT) and carbohydrate antigen 125 (CA125) encoded by the MUC16 mucin gene were evaluated as candidate predictors of outcome. Results: In first-line treatment, overall response, median progression-free survival (PFS) and two-year survival rate were 61.9%, 518 days and 67.3%, respectively. In second-line treatment, overall response, median PFS and median overall survival (OS) were 23.5%, 248 days and 651 days, respectively. The outcomes of the univariate analysis were as follows: normal D-dimer and CA125 levels at baseline were associated with better PFS and OS in first-line treatment; normal TAT and CA125 levels at baseline were associated with better PFS and OS in second-line treatment. According to the results of the multivariate analysis, normal D-dimer level was associated with longer PFS in first-line treatment, and only CA125 level at baseline was an independent predictor of both PFS and OS in second-line treatment. Conclusions: The results suggest that coagulo-fibrinolytic activity factors such as TAT, D-dimer or CA125 may be useful predictors of outcome in mCRC patients receiving BV in combination with chemotherapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Suenaga
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - S. Matsusaka
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - T. Watanabe
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - K. Takagi
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - Y. Kuboki
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - M. Ozaka
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - E. Shinozaki
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - K. Chin
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - N. Mizunuma
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| | - K. Hatake
- Cancer Institute Hospital, Tokyo, Japan; Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
| |
Collapse
|
|
43
|
Suenaga M, Matsusaka S, Takagi K, Kuboki Y, Watanabe T, Shinozaki E, Chin K, Mizunuma N, Hatake K. Potential markers predicting bevacizumab efficacy for metastatic colorectal cancer patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14107] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
|
44
|
Fukui N, Sato T, Kuboki Y, Aoki H. Bone tissue reaction of nano-hydroxyapatite/collagen composite at the early stage of implantation. Biomed Mater Eng 2008; 18:25-33. [PMID: 18198404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
The purpose of this study was to develop a new biodegradable bone substitute materials consisting of synthesized nano-size hydroxyapatite (nano-HAp) and Type I biodegradable honeycomb collagen sponge (HCS) composites. Bone defects in rabbit mandibles were prepared by a drill, and the composites were implanted into the bone defects. The HCS only and the HCS/calcined hydroxyapatite (HAp) composite were used as comparative materials. The bone tissues reaction at the early stage within 3 weeks after implantaion was investigated histologically. Amounts of new bone formation were determined by NIH-image analysis software using the histological sections. The amounts of the new bone formation were largest in the nano HAp/HCS compared to the comparative materials. Within 2 weeks after implantation, the nano-HAp/HCS composite was more rapidly exchanged by new bone than the comparative materials. From these results it was considered that the nano-HAp/HCS composites can be used as an effective biodegradable bone substitutive material.
Collapse
Affiliation(s)
- N Fukui
- Department of Oral Health, School of Life Dentistry at Tokyo, The Nippon Dental University, Chiyoda-ku, Tokyo, Japan.
| | | | | | | |
Collapse
|
|
45
|
Suenaga M, Mizunuma N, Chin K, Kuboki Y, Shizozaki E, Yamaguchi T, Muto T, Hatake K. Preventive approach to allergic reaction to oxaliplatin. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14569 Background: Allergic reaction to oxaliplatin is a chronic adverse event in the treatment of cancer. Patients with colorectal cancer were given FOLFOX4, using preventive approaches composed of two steps. Methods: Step I included 40 mg famotidine, 8 mg dexamethasone from the first cycle and 50 mg of diphenhydramine after cycle 4. In step II, for the patients who had a reaction but not a severe one in step I, a 20 mg dose of dexamethasone and four-hour oxaliplatin infusion were administered. Results: Forty-eight patients (15.1%) presented with allergic reaction, divided into group A receiving step I except diphenhydramine and B undergoing all of step I. Significant delay on occurrence was observed in group B. Thirty patients underwent step II. Prevention success (well-prevented) was defined as no reaction in two or more treatments. Allergic reaction appeared again in eleven patients (not well-prevented, 36.7%), but most well-prevented patients got four months longer treatment time with no reaction than not well-prevented patients. Conclusions: In our preventive approach, administration of H-1RA was effective in delaying the occurrence of allergic reaction to oxaliplatin, and increased dose of dexamethasone 20 mg and prolongation of oxaliplatin infusion from 2 to 4 hours was succeeded in continuing the FOLFOX4. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | - K. Chin
- Cancer Institute Hospital, Tokyo, Japan
| | - Y. Kuboki
- Cancer Institute Hospital, Tokyo, Japan
| | | | | | - T. Muto
- Cancer Institute Hospital, Tokyo, Japan
| | - K. Hatake
- Cancer Institute Hospital, Tokyo, Japan
| |
Collapse
|
|
46
|
Jansen JA, Vehof JWM, Ruhé PQ, Kroeze-Deutman H, Kuboki Y, Takita H, Hedberg EL, Mikos AG. Growth factor-loaded scaffolds for bone engineering. J Control Release 2005; 101:127-36. [PMID: 15588899 DOI: 10.1016/j.jconrel.2004.07.005] [Citation(s) in RCA: 162] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2004] [Accepted: 07/02/2004] [Indexed: 11/17/2022]
Abstract
The objective of the study presented here was to investigate the bone inductive properties as well as release kinetics of rhTGF-beta1- and rhBMP-2-loaded Ti-fiber mesh and CaP cement scaffolds. Therefore, Ti-fiber mesh and porous CaP cement scaffolds were provided with these growth factors and inserted in subcutaneous and cranial implant locations in rats and rabbits. In vitro, a rapid release of rhTGF-beta1 was observed during the first 2 h of the Ti-fiber mesh scaffolds. During this time, more than 50% of the total dose of rhTGF-beta1 was released. Following this initial peak, a decline in the level of rhTGF-beta1 occurred. After 1 week, the entire theoretical initial dose was observed to have been released. This in contrast to the rhTGF-beta1 and rhBMP-2 release of the porous CaP cement scaffolds. Here, no substantial initial burst release was observed. The scaffolds showed an initial release of about 1% after 1 day, followed by an additional marginal release after 1 week. Histological analysis revealed excellent osteoconductive properties of non-loaded Ca-P material. Inside non-loaded Ti-mesh fiber scaffolds, also bone ingrowth occurred. Quantification of the bone ingrowth showed that bone formation was increased significantly in all scaffold materials by administration of rhTGF-beta1 and rhBMP-2. Consequently, we conclude that the release kinetics of growth factors from porous CaP cement differs from other scaffold materials, like metals and polymers. Nevertheless, orthotopic bone formation in a rabbit cranial defect model was stimulated in rhTGF-beta1- and rhBMP-2-loaded CaP cement and Ti-fiber mesh scaffolds compared with non-loaded implants.
Collapse
Affiliation(s)
- J A Jansen
- Department of Periodontology and Biomaterials, University Medical Center, THK 117, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
|
47
|
Kuboki Y, Kikuchi M, Takita H, Yoshimoto R, Nakayama Y, Matsuda T, Ikada Y. Laser-perforated membranous biomaterials induced pore size-dependent bone induction when used as a new BMP carrier. Connect Tissue Res 2004; 44 Suppl 1:318-25. [PMID: 12952216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Previously we found that laser perforation of a collagen membrane (35 microm thickness, Koken Co., Tokyo) produced an effective bone morphogenetic protein (BMP) carrier, if the created pore sizes were larger than 0.5 mm. In this study we applied the same technique to create pores of 0.2 and 1.0 mm in a thicker (1.2 mm thickness) porous biodegradable membrane made of polylactic acid and an epsilon-caprolactone copolymer (PLA-CL) to obtain an effective membranous BMP carrier with higher mechanical strength. Pieces of PLA-CL (0.5 x 1.0 x 0.12 cm) combined with rhBMP-2 (5 microg) were implanted subcutaneously into rats and processed for analyses at 1-3 weeks. The laser-perforated PLA-CL membranes equipped with 1.0 mm pores induced mineralization beginning from the margins of the pores judging from the X-ray patterns, but bone formation seemed to proceed irregularly inside the pores. In the perforated PLA-CL membrane with 1.0-mm pores bone formation did not significantly increase compared with the nonperforated one. This was due to the fact that the PLA-CL membrane was already a porous structure (85% porosity). In contrast with laser-perforated PLA-CL 0.2 mm pores, bone was induced on the collagen fibers and fiber bundles inside the pores. The different patterns of bone formation between the PLA-CL membranes with 1.0 and 0.2 mm pores seemed to be related to the active formation of perpendicular collagen fibers through the 0.2 mm pores.
Collapse
Affiliation(s)
- Y Kuboki
- Department of Oral Health Science, Graduate School of Dental Medicine, Hokkaido University, Sapporo, Japan.
| | | | | | | | | | | | | |
Collapse
|
|
48
|
Takita H, Vehof JWM, Jansen JA, Yamamoto M, Tabata Y, Tamura M, Kuboki Y. Carrier dependent cell differentiation of bone morphogenetic protein-2 induced osteogenesis and chondrogenesis during the early implantation stage in rats. ACTA ACUST UNITED AC 2004; 71:181-9. [PMID: 15368268 DOI: 10.1002/jbm.a.30152] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
To evaluate the osteoinductive effects of recombinant human bone morphogenetic protein (rhBMP)-2 during the early stages of rat ectopic bone formation, we prepared two distinct carriers. Two carriers, insoluble bone matrix (IBM) and fibrous glass membrane (FGM) were combined with rhBMP-2 and implanted into the backs of rats to evaluate the osteoinductive effects of the two rhBMP-2 carrier systems. Insoluble bone matrix particle size was 320 to 620 microm. Fibrous glass membrane was constructed from unwoven glass fibers 1 microm in diameter. Alkaline phosphatase (ALP) activity and type II collagen were detected in IBM/rhBMP-2 at 5 days postimplantation. Calcium (Ca) was also detected in IBM/rhBMP-2 at 7 and 9 days postimplantation. In contrast, ALP and type II collagen were detected in FGM/rhBMP-2 at 7 days. Calcium was undetected, indicating that the bone formation in IBM/rhBMP-2 proceeded faster than in FGM/rhBMP-2 during the early stage of BMP-induced osteogenesis. In addition, mRNA expression level of KDR, a receptor for vascular endothelial growth factor, was also increased in IBM/rhBMP-2. To investigate the in vivo release profile of rhBMP-2, iodine 125 ((125)I)-labeled BMP-2-incorporating IBM and FGM implants were inserted into the back subcutis of mice. More than 60% of the rhBMP-2 was released from the IBM/rhBMP-2 carrier within 1 day after implantation, whereas 50% of the rhBMP-2 was released from the FGM/rhBMP-2 10 days postimplantation. These results indicated that osteo- and chondrogenesis depends highly upon the geometry of the carrier and the in situ retention of rhBMP-2 during the early stage of rhBMP-2 induced bone formation.
Collapse
Affiliation(s)
- H Takita
- Department of Oral Health Science, Graduate School of Dental Medicine, Hokkaido University, N-13, W-7, Kita-ku, Sapporo 060-8586, Japan.
| | | | | | | | | | | | | |
Collapse
|
|
49
|
Ojima Y, Mizuno M, Kuboki Y, Komori T. In vitro effect of platelet-derived growth factor-BB on collagen synthesis and proliferation of human periodontal ligament cells. Oral Dis 2003; 9:144-51. [PMID: 12945596 DOI: 10.1034/j.1601-0825.2003.02906.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVES Platelet-derived growth factor (PDGF)-BB is a polypeptide growth factor which has been shown to stimulate periodontal regeneration. In this study, we investigated the time- and dose-dependent effect of PDGF-BB on the proliferation and collagen synthesis of human periodontal ligament (PDL) cells. MATERIALS AND METHODS For the proliferation assay, PDL cells were cultured in 0.01-10 ng ml(-1) of PDGF-BB for 12 or 24 h, and cell numbers were counted. For the collagen synthesis assay, PDL cells were cultured in 0.1-10 ng ml(-1) of PDGF-BB for 1 to 24 h. The ratio of collagen content in total protein was evaluated, and the gene expression of type I collagen was assessed quantitatively by Northern blotting analysis. RESULT AND CONCLUSIONS PDGF-BB stimulated the proliferation of PDL cells in a time- and dose-dependent manner with the maximum effect at 10 ng ml(-1). PDGF-BB induced the collagen synthesis of PDL cells with the maximum effect for 24-h treatment, and 1 ng ml(-1) of PDGF-BB. PDGF-BB exhibits an inverse dose-dependent effect on proliferation and collagen synthesis by PDL cells. These findings suggest that PDGF-BB is one of the important regulators of the maintenance of the extracellular matrix in PDL, and may play an important role in the regeneration of PDL.
Collapse
Affiliation(s)
- Y Ojima
- Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
| | | | | | | |
Collapse
|
|
50
|
Vehof JWM, Takita H, Kuboki Y, Spauwen PHM, Jansen JA. Histological characterization of the early stages of bone morphogenetic protein-induced osteogenesis. J Biomed Mater Res 2002; 61:440-9. [PMID: 12115469 DOI: 10.1002/jbm.10216] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
On the basis of currently available knowledge, we hypothesize that the initial bone formation, as induced by bone morphogenetic protein (BMP), is influenced by the chemical composition and three-dimensional spatial configuration of the used carrier material. Therefore, in the current study, the osteoinductive properties of porous titanium (Ti) fiber mesh with a calcium phosphate (Ca-P) coating (Ti-CaP), insoluble bone matrix (IBM), fibrous glass membrane (FGM), and porous particles of hydroxy apatite (PPHAP) loaded with rhBMP-2 were compared in a rat ectopic assay model at short implantation periods. Twelve Ti-CaP, 12 IBM, 12 FGM, and 12 PPHAP implants, loaded with rhBMP-2, were subcutaneously placed in 16 Wistar King rats. The rats were sacrificed at 3, 5, 7, and 9 days post-operative, and the implants were retrieved. Histological analysis demonstrated that IBM and Ti-CaP had induced ectopic cartilage and bone formation by 5 and 7 days, respectively. However, in PPHAP, bone formation and cartilage formation were seen together at 7 days. At 9 days, in Ti-CaP, IBM, and PPHAP, cartilage was seen together with trabecular bone. At 9 days, in FGM, only cartilage was observed. Quantitative rating of the tissue response, using a scoring system, demonstrated that the observed differences were statistically significant (Wilcoxon rank sum test, p < 0.05). We conclude that IBM, CaP-coated Ti mesh, FGM, and PPHAP provided with rhBMP-2 can indeed induce ectopic bone formation with a cartilaginous phase in a rat model at short implantation periods. Considering the different chemical composition and three-dimensional spatial configuration of the carrier materials used, these findings even suggest that endochondral ossification is present in rhBMP-2-induced osteogenesis, even though the amount of cartilage may differ.
Collapse
Affiliation(s)
- J W M Vehof
- Department of Biomaterials, College of Dental Science, University Medical Center Nijmegen, P. O. Box 9101, the Netherlands
| | | | | | | | | |
Collapse
|